Research & Development

Graybug Vision secures £66m to advance retina and glaucoma clinical programs

Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), today announced the securing of an $80 million (£66m) Series C financing.

Angel-funded Siamab completes £166m exit with large commercial-stage biopharma

Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202m (£166m) with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialise antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform.

Mexico-based Sanfer gets £413m investment from CDPQ

Caisse de dépôt et placement du Québec (CDPQ), a Canadian long-term institutional investor, has agreed to make a minority investment of $500m (£413.8m) in Mexican pharmaceutical company Sanfer.

Xynomic Research Institute successfully designs series of potent RET kinase inhibitors

Xynomic Pharmaceuticals Holdings, a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (XRI) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design.

GeneCentric Therapeutics acquires Select ImmunoGenomics

GeneCentric Therapeutics announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of immuno-oncology drugs.

Landos Biopharma completes £49.7m series B financing

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the successful completion of its $60m (£49.7m) Series B financing round.

Eidos Therapeutics confirms receipt of non-binding proposal from BridgeBio Pharma to acquire shares

Eidos Therapeutics has received a non-binding proposal dated August 8, 2019 (the Proposal) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (BridgeBio), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio.

Boehringer Ingelheim, MD Anderson to jointly advance new cancer therapies

Boehringer Ingelheim has forged a multi-year partnership with The University of Texas MD Anderson Cancer Center to carry out joint research towards rapid advancement of new therapies for various forms of cancers.

Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m

Jazz Pharmaceuticals has acquired US-based clinical-stage biotechnology company Cavion for a total potential consideration of $312.5m (£258.9m).